Beijing Beilu Pharmaceutical Co., Ltd.
Announcement on the Proposed Selection of Pioglitazone and Metformin Hydrochloride Extended-Release Tablets in the 12th National Centralized Drug Procurement
The Company and all members of the Board of Directors guarantee the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or material omissions.
Recently, Beijing Beilu Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") participated in the 12th National Centralized Drug Procurement organized by the National Centralized Drug Procurement Office (hereinafter referred to as the "Procurement Office"). The Company's Pioglitazone and Metformin Hydrochloride Extended-Release Tablets were selected. The relevant situation is hereby announced as follows:
I. Basic Information of Proposed Selection